Risk of HIV-associated Hodgkin lymphoma during the first months after initiation of combination antiretroviral therapy
| Autor: | PS Rosenberg, Elisabeth Rouveix, V Martinez, James J. Goedert, Eric A. Engels, I Poizot-Martin, M Partisani, Emilie Lanoy, Dominique Costagliola, F Fily, AS Lascaux |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Cart
Oncology Cancer Research medicine.medical_specialty Epidemiology Human immunodeficiency virus (HIV) medicine.disease_cause Bioinformatics lcsh:RC254-282 Meeting Abstracts lcsh:Infectious and parasitic diseases Exposure group immune system diseases Internal medicine parasitic diseases mental disorders Medicine lcsh:RC109-216 Cd4 cell count business.industry Incidence (epidemiology) virus diseases lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Antiretroviral therapy Infectious Diseases nervous system Hodgkin lymphoma business |
| Zdroj: | Infectious Agents and Cancer Infectious Agents and Cancer, Vol 5, Iss Suppl 1, p A71 (2010) |
| ISSN: | 1750-9378 |
| Popis: | Background Since the advent of combination antiretroviral therapy (cART), several studies have described an increase in the incidence of Hodgkin lymphoma (HL). This increase has been postulated to be linked with immunologic mechanisms occurring at cART initiation. Relationships between the CD4 cell count and the risk of HL have also been investigated. Our study aimed to evaluate the risk of HL by use of cART and its duration. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink